HPLC Verified
Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

5mg triple-agonist research peptide
Retatrutide — development designation LY3437943 — represents the current frontier of incretin receptor pharmacology: a single peptide molecule engineered to simultaneously activate three distinct G protein-coupled receptors. Its triple agonist architecture distinguishes it from all earlier compounds in the incretin class and positions it as among the most potent metabolic research tools currently under investigation.
The incretin system — comprising GLP-1 and GIP, secreted from intestinal L- and K-cells respectively in response to nutrient ingestion — has been pharmacologically validated across two decades of drug development. GLP-1 receptor agonists act on beta-cell insulin secretion, gastric emptying, and hypothalamic appetite circuits; GIPR agonism adds complementary effects on adipose insulin sensitivity and bone metabolism. Retatrutide extends this framework by adding glucagon receptor (GCGR) agonism as a third simultaneous input — a receptor historically associated with hyperglycaemia risk when activated alone, but which drives potent hepatic fatty acid oxidation and thermogenic energy expenditure when balanced against GLP-1 and GIP activity. The result is a single molecule that engages three distinct G protein-coupled receptor signalling cascades concurrently, enabling the study of multi-receptor metabolic biology that cannot be dissected using earlier single- or dual-agonist tools.
The Phase 2 randomised controlled trial published by Jastreboff and colleagues in the New England Journal of Medicine (2023) provided the most comprehensive pharmacological dataset available for any triple incretin receptor agonist. At the highest tested dose, participants achieved mean weight reductions of approximately 17.5% at 24 weeks, extending to 24.2% by 48 weeks — figures substantially exceeding those reported for semaglutide or tirzepatide in comparable trial designs. Secondary endpoints documented significant reductions in waist circumference, visceral fat fraction by MRI, HbA1c, triglycerides, and hepatic fat content, offering a multi-domain view of the compound's metabolic pharmacodynamics across adipose, glycaemic, and hepatic compartments.
The preceding Phase 1 study by Nahra and colleagues (2021, Diabetes Care) established the human pharmacokinetic and pharmacodynamic profile, confirming dose-dependent reductions in postprandial glucose and body weight with a once-weekly subcutaneous dosing schedule and an adverse event pattern consistent with GLP-1 class effects.
As a triple receptor agonist with precisely characterised pharmacology, retatrutide is a valuable tool for dissecting the relative contributions of GLP-1R, GIPR, and GCGR signalling to metabolic phenotypes in preclinical models. Comparative studies using selective receptor antagonists or receptor-knockout mouse lines alongside retatrutide administration can help deconvolve individual receptor contributions from the composite pharmacological signal — an important methodological approach for understanding multi-receptor incretin biology. Growing interest in MASLD/NASH research models is further supported by Phase 2 hepatic fat reduction data, providing a compelling rationale for preclinical investigation of GCGR-mediated hepatic lipid flux.
This content is for informational purposes only and reflects the state of clinical and preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.
Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.
Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.
Each vial is traceable to its synthesis batch, testing date, and analytical records.
European stock stored at optimal temperature from synthesis to dispatch.
Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.
Certificate of Analysis issued for every batch, available for download on request.
Peer-reviewed research supporting Retatrutide investigation.
Pivotal Phase 2 randomised controlled trial of retatrutide in adults with obesity. At the highest dose, 24-week mean weight reduction reached 17.5%, with 48-week data showing 24.2% reduction — figures substantially exceeding prior generation incretin agonists. The trial also documented significant improvements in cardiometabolic markers including HbA1c, triglycerides, and hepatic fat fraction.
View on PubMedPreclinical characterisation study establishing retatrutide's pharmacological profile as a balanced triple agonist. In diet-induced obese and diabetic rodent models, LY3437943 produced superior reductions in body weight, food intake, and glycaemic markers compared to dual-agonist comparators, validating the multi-receptor pharmacological concept and defining receptor binding affinities and signalling characteristics.
View on PubMedFirst-in-human Phase 1 safety and pharmacodynamics study of retatrutide in participants with type 2 diabetes. Single and multiple ascending doses demonstrated dose-dependent reductions in postprandial glucose and body weight, with a pharmacokinetic profile supporting once-weekly subcutaneous dosing and an adverse event pattern consistent with GLP-1 class effects.
View on PubMedAll studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.
Answers to the most frequently asked questions about Retatrutide.
Other Metabolic research compounds from our catalogue.
Retatrutide (LY3437943) is the first synthetic peptide engineered to simultaneously activate three distinct G protein-coupled receptors — GLP-1R, GIPR, and GCGR — within a single molecular scaffold. This concurrent tri-receptor engagement enables coordinated modulation of insulin secretion, gastric motility, adipose metabolism, and hepatic gluconeogenesis via three complementary intracellular signalling cascades.
The Phase 2 randomised controlled trial published by Jastreboff et al. (2023, NEJM) reported a mean body weight reduction of 24.2% at 48 weeks in the highest-dose cohort — a magnitude exceeding prior-generation incretin receptor agonists in comparable timeframes. Secondary endpoints documented significant improvements in waist circumference, visceral fat fraction (MRI-PDFF), and cardiometabolic risk markers.
Preclinical studies in diet-induced obese and diabetic rodent models demonstrate concurrent improvements in insulin sensitivity, postprandial glucose excursions, and glycaemic control markers following triple agonist administration. The combined activation of GLP-1R and GIPR creates complementary insulinotropic signals, while GCGR engagement modulates hepatic glucose output via adenylyl cyclase-mediated pathways.
Glucagon receptor agonism — the third pharmacological arm of retatrutide — drives hepatic fatty acid oxidation and thermogenic energy expenditure, pathways largely inaccessible to GLP-1 or dual GLP-1/GIP compounds alone. Preclinical energy balance studies document increased oxygen consumption and brown adipose tissue activation consistent with the enhanced thermogenic component of the triple agonist mechanism.
Phase 2 trial secondary endpoints revealed significant reductions in liver fat fraction measured by MRI-PDFF in participants receiving retatrutide, consistent with glucagon receptor-mediated stimulation of hepatic beta-oxidation. These data position retatrutide as a research tool for investigating the intersection of incretin pharmacology and metabolic-associated steatotic liver disease (MASLD).
Retatrutide simultaneously activates three distinct G protein-coupled receptors: the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Each receptor mediates different aspects of metabolic physiology — GLP-1R primarily influences insulin secretion, satiety, and gastric emptying; GIPR modulates insulin secretion and adipocyte function; GCGR drives hepatic glucose production and thermogenic energy expenditure. The triple pharmacology is intended to leverage additive or synergistic effects across all three pathways.
Semaglutide is a selective GLP-1R agonist (single agonist). Tirzepatide is a dual GLP-1R/GIPR agonist. Retatrutide adds glucagon receptor agonism to this pharmacological profile, creating a triple agonist with distinct metabolic effects — particularly enhanced hepatic lipid oxidation and thermogenesis attributable to the GCGR component. The Phase 2 trial data suggest that this additional receptor target contributes meaningfully to the magnitude of weight loss observed.
The primary preclinical models reported in the literature include diet-induced obese (DIO) mice and rats, db/db diabetic mice, and GLP-1R/GIPR/GCGR transgenic or knockout mouse lines used to deconvolve receptor-specific contributions. For mechanistic hepatic studies, high-fat/high-fructose diet rodent models of non-alcoholic steatohepatitis (NASH) have been used to assess the compound's effects on hepatic lipid accumulation.
As of the current research period, retatrutide has not received regulatory approval for any therapeutic indication. It remains in clinical development. UNIK LAB supplies retatrutide exclusively for in vitro and preclinical research purposes by qualified researchers.
Lyophilised retatrutide should be stored at 2–8°C in sealed, desiccated vials protected from light. As a larger peptide (4,679.5 Da), it is more susceptible to aggregation and degradation than smaller research peptides. Reconstitution should be performed in sterile bacteriostatic water or appropriate buffer; vortexing should be avoided in favour of gentle rotation. Reconstituted solution should be stored at 2–8°C and used within 14 days.
Standard systems include HEK293 cells stably expressing human GLP-1R, GIPR, or GCGR for cAMP accumulation and β-arrestin recruitment assays. For metabolic endpoint studies, INS-1 or MIN6 beta-cell lines are used for insulin secretion assays; primary hepatocytes for gluconeogenesis and lipid flux studies; and 3T3-L1 adipocytes for lipid metabolism endpoints. Multi-receptor studies require careful selection of cell systems expressing defined receptor complements.
UNIK LAB's retatrutide achieves ≥98% purity by HPLC with MS identity confirmation of the full molecular weight. Given the peptide's complexity (>4,600 Da), we recommend researchers also verify sequence integrity via peptide mapping or amino acid analysis for critical experiments. Full CoA with HPLC chromatogram, MS spectrum, and batch traceability is provided with each order.